CNTB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast CNTB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTB is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.67

High

10.00

Current: 0.000

Low

7.00

Averages

8.67

High

10.00

BTIG

Buy

initiated

$10

2025-10-31

Reason

BTIG

Price Target

$10

2025-10-31

initiated

Buy

Reason

BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.

Northland

Outperform

initiated

$7.50

2025-07-22

Reason

Northland

Price Target

$7.50

2025-07-22

initiated

Outperform

Reason

Northland initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target.

Northland

Carl Byrnes

Outperform

initiated

$7.50

2025-07-22

Reason

Northland

Carl Byrnes

Price Target

$7.50

2025-07-22

initiated

Outperform

Reason

As previously reported, Northland analyst Carl Byrnes initiated coverage of Connect Biopharma with an Outperform rating and $7.50 price target. Lead candidate rademikibart is positioned as the first biologic for treating acute exacerbations in asthma and COPD, addressing \"a major unmet need\" and \"poised to define a new therapeutic category,\" the analyst tells investors. Topline data from its Phase 2 studies is expected in the first half of 2026, notes the analyst, who sees peak sales potential exceeding $5B.

H.C. Wainwright

Brandon Folkes

initiated

2025-06-12

Reason

H.C. Wainwright

Brandon Folkes

Price Target

2025-06-12

initiated

Reason

H.C. Wainwright analyst Brandon Folkes initiated coverage of Connect Biopharma with a Buy rating and $7 price target. The analyst believes the company's lead asset, rademikibart, has the potential to be a best-in-class treatment in acute exacerbations of asthma and COPD. With a current negative enterprise value, Connect shares offer a "compelling risk/reward considering the potentially very large market opportunity a best-in-class asthma drug could target," the analyst tells investors in a research note.

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-03-31

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-03-31

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Connect Biopharma Holdings Ltd (CNTB.O) is -1.96, compared to its 5-year average forward P/E of -3.49. For a more detailed relative valuation and DCF analysis to assess Connect Biopharma Holdings Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.49

Current PE

-1.96

Overvalued PE

-0.24

Undervalued PE

-6.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.42

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

4.11

Undervalued EV/EBITDA

-8.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2091.34

Current PS

46251.92

Overvalued PS

11114.95

Undervalued PS

-6932.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CNTB News & Events

Events Timeline

No data

News

6.0

2025-11-13Benzinga

BTIG Affirms Buy Rating for Connect Biopharma Holdings, Keeps $10 Price Target Intact

9.5

2025-11-12Newsfilter

Connect Biopharma Announces Financial Results for Q3 2025 and Offers Business Update

4.0

2025-10-31Benzinga

Immuneering Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Friday

People Also Watch

Frequently Asked Questions

What is Connect Biopharma Holdings Ltd (CNTB) stock price today?

The current price of CNTB is 2.23 USD — it has increased 0 % in the last trading day.

What is Connect Biopharma Holdings Ltd (CNTB)'s business?

Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.

What is the price predicton of CNTB Stock?

What is Connect Biopharma Holdings Ltd (CNTB)'s revenue for the last quarter?

Connect Biopharma Holdings Ltd revenue for the last quarter amounts to 16.00K USD, decreased -98.69 % YoY.

What is Connect Biopharma Holdings Ltd (CNTB)'s earnings per share (EPS) for the last quarter?

Connect Biopharma Holdings Ltd. EPS for the last quarter amounts to -0.31 USD, increased 34.78 % YoY.

What changes have occurred in the market's expectations for Connect Biopharma Holdings Ltd (CNTB)'s fundamentals?

The market is revising Upward the revenue expectations for Connect Biopharma Holdings Limited (CNTB) for FY2025, with the revenue forecasts being adjusted by 203.75% over the past three months. During the same period, the stock price has changed by 12.63%.

How many employees does Connect Biopharma Holdings Ltd (CNTB). have?

Connect Biopharma Holdings Ltd (CNTB) has 62 emplpoyees as of January 09 2026.

What is Connect Biopharma Holdings Ltd (CNTB) market cap?

Today CNTB has the market capitalization of 124.66M USD.